Marius Pearson

Oxford PharmaGenesis and OriginTrail to introduce collaborative, AI-ready medical knowledge ecosystem driving the next generation of agentic science

A vast amount of valuable clinical trial information exists in the world but much of it is fragmented, hard to verify and difficult to use, slowing medical research and patient care. This lack of connectivity delays research, complicates evidence synthesis, and limits the ability of healthcare professionals, patients and other stakeholders to access clear, reliable information.

To address these challenges, Trace Labs, the core developers of OriginTrail, and Oxford PharmaGenesis have partnered on a groundbreaking initiative to globally connect and verify medical knowledge.

Read More

Putting patients first: unlocking the power of lived experience through Patient Experience Mapping

Over the past two months, we’ve had the privilege of engaging with the healthcare communications and patient engagement communities at MAPS EMEA, ISMPP Annual, ISPOR US and Patients as Partners Europe. Across continents and conversations, one theme clearly stood out: patient involvement is no longer optional – it is essential.

Read More

Multiple Sclerosis Awareness Week – shining a light on unmet needs

Multiple Sclerosis Awareness Week – shining a light on unmet needs   Vast strides have been made in multiple sclerosis (MS) treatment and care in recent years. Despite these advancements, unmet needs remain for people living with this lifelong condition that can severely impact many aspects of their lives. MS Brain Health – time matters 2024, […]

Read More

Evolution of our operating model in the USA

News and events We are thrilled to announce a significant shift in our office model that will enhance our ability to attract top talent from across the USA, build a more flexible and sustainable culture, and – importantly – work from locations and time zones that are closer to our clients. Starting this year, we are transitioning […]

Read More

New ESG report highlights our commitment to sustainability

We are excited to announce the release of our latest Environmental, Social, and Governance (ESG) report.

Read More

Rare Disease Day – using HealthScience communications to connect the dots

As HealthScience professionals, we spend a lot of time thinking about data. How many patients are there worldwide? How many days do these patients spend in hospital per year? How much more effective is drug X than drug Y? On Rare Disease Day, there are a lot of numbers to think about too. According to […]

Read More

A fond farewell as Graham retires

Graham Shelton, our Founder and Chairman, stepped down at the end of December 2024. We were proud to mark his retirement at our Oxford party, and present him with a book of memories from current and former colleagues and clients from around the world.

Read More

Revolutionizing pharma training: key takeaways from LTEN

Revolutionizing pharma training: key takeaways from LTEN Unveiling the future of pharmaceutical training, we gathered invaluable insights at the Life Sciences Trainers & Educators Network (LTEN) Annual Conference. Training professionals are constantly striving for impactful learning experiences that not only educate, but also induce tangible behaviour change. Our Learning Design Team Lead, Jamie Singer, attended […]

Read More

AI tools for systematic literature reviews

AI tools for systematic literature reviews AI can help us to develop high-quality work, including systematic literature reviews (SLRs) for publication. In this article, published in the September edition of The MAP, the official newsletter of the International Society for Medical Publication Professionals, Polly Field, Richard White and Tomas Rees from Oxford PharmaGenesis provide guidance […]

Read More

A HealthScience approach to integrated evidence generation planning

A HealthScience approach to integrated evidence generation planning What is an integrated evidence generation plan (IEGP)? An IEGP brings together all evidence generation work, across geographies, to ensure the delivery of robust evidence throughout the product life cycle, helping to improve patient care and outcomes. Why develop an IEGP now? Stakeholder demands for robust and […]

Read More